Breaking News Instant updates and real-time market news.

2017-04-13 16:10:04

NBRV

Nabriva Therapeutics

$11.08

-0.09 (-0.81%)

16:10

04/13/17

04/13

16:10

04/13/17

16:10

Nabriva Therapeutics to present data at ECCMID

Nabriva Therapeutics announced that it will present data at the 27th European Congress of Clinical Microbiology and Infectious Diseasestaking place in Vienna, Austria from April 22-25. In total, the company will showcase nine abstracts, three of which were selected as oral presentations. These data are part of a growing body of evidence supporting lefamulin's profile as a potential first-line, empiric treatment for the key pathogens, including multidrug resistant strains, that are known to cause community-acquired bacterial pneumonia. "Antibacterial resistance continues to spread, rendering currently available antibiotics less effective. It is critical that new classes of antibiotics continue to be developed to provide physicians treatment options for patients with serious infections," said Steven P. Gelone, Pharm.D., Chief Development Officer at Nabriva. "With a novel mechanism of action, lefamulin provides a targeted spectrum of activity that covers the most common bacterial causes of CABP, including multidrug resistant strains and atypical pathogens. The data being presented at ECCMID are supportive of our ongoing Phase 3 clinical development program, and we look forward to reporting top-line data from our first pivotal trial, known as LEAP 1, in the third quarter of 2017."

Leerink analyst Paul Matteis resumed coverage of Nabriva Therapeutics with an Outperform rating and $14 price target as he continues to believe the company is "unique" among its late stage antibiotic peers.

RBC Capital analyst Adnan Butt says that Nabriva's stock is "undervalued based on numerous data points." The analyst thinks that the stock should rise significantly when data for the company's antibiotic lefamulin is released in 2H17. Butt expects the data from the trial to be positive, and he keeps a $22 price target and an Outperform rating on the stock.

03/10/17

LEER

03/10/17NO CHANGETarget $20LEEROutperform

Nabriva Therapeutics price target raised to $20 from $14 at Leerink

Leerink analyst Paul Matteis raised his price target for Nabriva Therapeutics to $20 from $14 ahead of Phase 3 results in 2H17. His analysis of in vitro, pharmacokinetic, drug distribution, safety and skin efficacy data render the analyst optimistic that Phase 3 trials have reasonable odds of success, creating what he views as a favorable risk/reward for the stock. Matteis reiterates an Outperform rating on the shares.